16th Oct 2020 15:10
Synairgen plc
("Synairgen" or the "Company")
Exercise of Options and Total Voting Rights
Southampton, UK - 16 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that the Company has applied for a total of 16,462 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be issued and allotted pursuant to the exercise of options by Dr Victoria Tear, PDMR.
The Ordinary Shares were exercised at a price of 1 pence by Dr Victoria Tear and subsequent to this, the Company was notified on 16 October that on that same day, Dr Victoria Tear sold 8,367 Ordinary Shares at a price of 195.5 pence per Ordinary Share to meet subscription and taxation costs.
As a result of the exercise of options, application has been made for the 16,462 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on or around 22 October 2020.
The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 165,104,676 Ordinary Shares. Accordingly, the figure of 165,104,676 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)
finnCap - Nominated Adviser and Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane / Sunila de Silva (ECM)
Numis - Joint Broker +44 (0) 20 7260 1000
James Black / Freddie Barnfield / Duncan Monteith
Consilium Strategic Communications - Financial Media and Investor +44 (0) 20 3709 5700
Relations Adviser
Mary-Jane Elliott / Sue Stuart / Olivia Manser
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | ||||||||||
a) | Name | Dr Victoria Tear | |||||||||
2. | Reason for notification | ||||||||||
a) | Position / status | Head of Laboratories, PDMR of the Company | |||||||||
b) | Initial notification / amendment | Initial Notification | |||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | Synairgen plc | |||||||||
b) | LEI | 213800IMMTOPPDF8HD24 | |||||||||
4. | Details of the transaction(s): | ||||||||||
a) | Description of the financial instrument Identification code | Options over ordinary shares of 1p each GB00B0381Z20 | |||||||||
b) | Nature of the transaction | Exercise of options over Ordinary Shares; and Sale of Ordinary Shares of 1p each
| |||||||||
c) | Price(s) and volume(s) |
| |||||||||
d) | Aggregated information Aggregated volume Price | n/a | |||||||||
e) | Date of the transaction | 16 October 2020 | |||||||||
f) | Place of the transaction | London Stock Exchange | |||||||||
Related Shares:
Synairgen